The purpose of this Registry is creating a database management that allows continuous monitoring characteristics, evolution, prognostic indicators and management of patients with ACS admitted in Portuguese Hospitals, and identify the appropriateness of clinical practice recommendations for diagnosis and treatment of ACS and monitor its evolution.

Population

All adult patients with Acute Coronary Syndrome (ACS) with <48 hours of evolution, admitted to Portuguese Hospitals.

Brief Title

Portuguese Registry on Acute Coronary Syndromes

Official Title

Portuguese Registry on Acute Coronary Syndromes

Brief Summary

The purpose of this Registry is creating a database management that allows continuous<br /> monitoring characteristics, evolution, prognostic indicators and management of patients with<br /> ACS admitted in Portuguese Hospitals, and identify the appropriateness of clinical practice<br /> recommendations for diagnosis and treatment of ACS and monitor its evolution.

Detailed Description

Cardiovascular diseases remain the principal causes of death in Portugal and approximately
one quarter of these are directly to ischemic heart disease, especially Acute Coronary
Syndromes (ACS).

In order to reduce mortality for ACS, a significant number of new drugs and new techniques
have been introduced into clinical practice, resulting in important heterogeneity of approach
and treatment of patients with ACS.

The Portuguese Society of Cardiology have sought to review and incorporate in its
recommendations the evidence to date, with the aim to standardize diagnosis and treatment of
patients with ACS, which is not always able to in daily practice.

Since it is essential to characterize the national reality of the ACS, the Portuguese Society
of Cardiology has promoted the Portuguese registry on Acute Coronary Syndromes, aimed at
bridging the knowledge gaps in this area of cardiovascular disease.

This will include all adult patients (≥ 18 years) diagnosed with Acute Coronary Syndrome
(ACS) with <48 hours of evolution. The inclusion is of responsibility of the last service of
Cardiology where the patient was hospitalized. The ACS is set to the presence of angina at
rest last 48 hours, with 1) ischemic electrocardiographic changes ST-segment deviations or
negative T waves, and / or 2) elevation of biomarker (cardiac troponin and CK-MB) above the
reference value. For diagnosis ACS with ST elevation is considered to be persistently
elevated (> 30 minutes) of the ST segment. The rest should be considered as ACS ST-segment
elevation. In the absence of angina, the SCA will be considered consistent elevation (curve
ascending / descending) biomarker (above reference value for cardiac troponin or higher 2
times the value of reference to the CK-MB) associated with other clinical manifestations such
as ill-defined chest discomfort or dyspnea.

Are included patients participating in clinical trials

Are excluded patients with MI after revascularization procedures (EAM type 4 and 5) and MI
type 2 (classification according to the redefinition of Myocardial Infarction, 2007 the Joint
ESC / ACCF / AHA / WHF Task Force)

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.